- Previous Close
12.46 - Open
12.34 - Bid 12.06 x --
- Ask 12.09 x --
- Day's Range
11.95 - 12.40 - 52 Week Range
11.80 - 24.25 - Volume
300,307 - Avg. Volume
553,084 - Market Cap (intraday)
1.571B - Beta (5Y Monthly) 2.17
- PE Ratio (TTM)
11.96 - EPS (TTM)
1.01 - Earnings Date Jan 29, 2025 - Feb 3, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
26.21
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
www.neurenpharma.comRecent News: NEU.AX
View MorePerformance Overview: NEU.AX
Trailing total returns as of 1/9/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NEU.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NEU.AX
View MoreValuation Measures
Market Cap
1.62B
Enterprise Value
1.28B
Trailing P/E
12.35
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.34
Price/Book (mrq)
4.61
Enterprise Value/Revenue
5.67
Enterprise Value/EBITDA
7.39
Financial Highlights
Profitability and Income Statement
Profit Margin
60.66%
Return on Assets (ttm)
59.56%
Return on Equity (ttm)
75.51%
Revenue (ttm)
193.34M
Net Income Avi to Common (ttm)
117.29M
Diluted EPS (ttm)
1.01
Balance Sheet and Cash Flow
Total Cash (mrq)
213.17M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
98.45M